fiercebiotech.com
Cure8 news brief
Why This Matters
This deal accelerates funding for a drug (RXC008) specifically targeting fibrosis in Crohn’s disease, an area with no approved anti‑fibrotic therapies and where patients often need surgery for strictures. If clinical trials succeed, it could lead to a first-in-class treatment option for fibrostenotic IBD.
Who Should Pay Attention
Patients with fibrostenotic Crohn’s disease, caregivers of people facing stricture-related surgery, IBD clinicians, and researchers focused on anti-fibrotic drug development.
Study Snapshot
Story typeBusiness news
Evidence typeMarket or Business News
Source depthFull source text
What To Know
New biotech company Fibrx Therapeutics will be formed by combining Skye Bioscience and Redx Pharma with $125 million in financing to advance fibrosis-focused drug candidates. The lead program, RXC008, is described as a GI‑restricted pan‑ROCK inhibitor entering a phase 2 trial for fibrostenotic Crohn’s disease; data are expected in H2 2028.
The article summarizes prior preclinical and phase 1 work, mentions FDA Fast Track designation for RXC008, and also notes other pipeline assets (a DDR inhibitor preclinical program and RXC007/zelasudil for lung fibrosis). The piece is primarily a business/financing report rather than a clinical study report.
Keep In Mind
This article is market and company‑announcement reporting. The described drug is entering phase 2 and has Fast Track designation, but phase 2 results are not yet available. Business financing and corporate merger details drive the story; clinical benefit remains to be demonstrated in trials.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationfiercebiotech.com
PublisherFierce Biotech
Indexed viaGoogle News
Source typeWeb article
PublishedAug 14, 2026, 6:09 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Crohn's Disease Market: Accelerating Growth and Pipeline Impact by 2034 – DelveInsight
This report summarizes recent late-stage trial results, regulatory actions, and new biosimilar launches that could affect treatment options, availability, and drug costs in Crohn’s disease over the coming years.
SKYE: Merger creates Fibrx, a well-funded fibrosis company advancing RXC008 for Crohn's disease
Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Stricture.
'Reverse mergers are increasingly popular': Caldera hops on Synlogic's Nasdaq listing
Caldera’s funding and Nasdaq listing mean the company can run phase 2 trials in ulcerative colitis and Crohn’s disease of a bispecific drug that targets two immune pathways. If successful, that approach could change...